The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
Publish Date
The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
Please login or register first to view this content.